HIV drug development: the next 25 years

作者: Charles Flexner

DOI: 10.1038/NRD2336

关键词: MedicineDrug developmentTreatment optionsDiseasePharmacologyDrug resistanceDrugHuman immunodeficiency virus (HIV)Intensive care medicinePharmacogenomicsPotential impact

摘要: The development of drugs for HIV infection began soon after the virus was discovered 25 years ago. Since then, progress has been substantial, but numerous uncertainties persist about best way to manage this disease. Here we review current treatment options, consider novel mechanisms that can be exploited existing drug targets, and explore potential targets. With a view next quarter century, whether resistance avoided, which classes will favoured over others, strategies are most likely succeed, impact pharmacogenomics individualized therapy.

参考文章(42)
Jeanne C. Keruly, Kelly A. Gebo, Gregory M. Lucas, Richard D. Moore, An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. Journal of Acquired Immune Deficiency Syndromes. ,vol. 39, pp. 195- 198 ,(2005)
Bartlett Jg, Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services. The Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service. ,vol. 10, ,(1998)
Heather J Ribaudo, Catia Marzolini, Todd Hulgan, David B Clifford, Richard B Kim, Edward P Acosta, Roy M Gulick, David W Haas, Camlin Tierney, Grant R Wilkinson, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. ,vol. 18, pp. 2391- 2400 ,(2004)
Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine. ,vol. 356, pp. 1723- 1735 ,(2007) , 10.1056/NEJMOA062744
R. E. Nettles, T. L. Kieffer, T. Parsons, J. Johnson, J. Cofrancesco, J. E. Gallant, K. A. Carson, R. F. Siliciano, C. Flexner, Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring Clinical Infectious Diseases. ,vol. 42, pp. 1189- 1196 ,(2006) , 10.1086/501458
L. A. Loeb, J. M. Essigmann, F. Kazazi, J. Zhang, K. D. Rose, J. I. Mullins, Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 1492- 1497 ,(1999) , 10.1073/PNAS.96.4.1492
Olle Karlstr??m, Filip Josephson, Anders S??nnerborg, Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. Journal of Acquired Immune Deficiency Syndromes. ,vol. 44, pp. 417- 422 ,(2007) , 10.1097/QAI.0B013E31802E2940
Robert Hegarty, Curtis R. Chong, Jun O. Liu, Robert F. Siliciano, Chloe L. Thio, Moira A. McMahon, Benjamin L. Jilek, Timothy P. Brennan, Lin Shen, Yan Zhou, Megan Wind-Rotolo, Sifei Xing, Shridhar Bhat, Braden Hale, The HBV Drug Entecavir — Effects on HIV-1 Replication and Resistance New England Journal of Medicine. ,vol. 356, pp. 2614- 2621 ,(2007) , 10.1056/NEJMOA067710
Yaoxing Huang, William A. Paxton, Steven M. Wolinsky, Avidan U. Neumann, Linqi Zhang, Tian He, Stanley Kang, Daniel Ceradini, Zhanqun Jin, Karina Yazdanbakhsh, Kevin Kunstman, Daniel Erickson, Elizabeth Dragon, Nathaniel R. Landau, John Phair, David D. Ho, Richard A. Koup, The role of a mutant CCR5 allele in HIV–1 transmission and disease progression Nature Medicine. ,vol. 2, pp. 1240- 1243 ,(1996) , 10.1038/NM1196-1240
Victor De Gruttola, Charles Flexner, Jonathan Schapiro, Michael Hughes, Mark Van Der Laan, Daniel R. Kuritzkes, Drug Development Strategies for Salvage Therapy: Conflicts and Solutions AIDS Research and Human Retroviruses. ,vol. 22, pp. 1106- 1109 ,(2006) , 10.1089/AID.2006.22.1106